2017_SBRT_Course Book

Overview

1. General outline 2. SBRT combined with targeted drugs 3. SBRT combined with immunotherapy 4. Safety of SBRT combined with novel drugs

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

35

/

Use of concurrent SRT and novel drugs in the DEGRO society

Targeted therapy simultan zur SBRT n (%)

Targeted therapy

Antikörper Bevacizumab Ipilimumab Panitumumab Trastuzumab Cetuximab

0

8 (30%) 7 (26%) 5 (19%) 14 (52%) 7 (26%) 7 (26%) 2 (7%) 4 (15%) 7 (26%) 6 (22%) 5 (19%) 5 (19%)

Nivolumab

Pembrolizumab

Tyrosine Kinase Inhibitoren Vemurafenib

Sorafenib Erlotinib Lapatinib Gefitinib Crizotinib

Ø Concurrent treatment with SRT and targeted drugs performed by many institutions, already

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

36

/